ResearcherUniversity of Colorado AnschutzActive in the last 2 years

Ioannis A. Ziogas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6742-6909; OpenAlex author ID A5087953432. Sources: OpenAlex.

Their work

Papers: 4 (first author 2, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 4

Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making. Co-author DOI 10.3390/cancers18010094 ↗
Comparison of Invasive Pancreatic Ductal Adenocarcinoma versus Intraductal Papillary Mucinous Neoplasm: A National Cancer Database Analysis. Co-author DOI 10.3390/cancers15041185 ↗
The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer. First author DOI 10.3389/fonc.2022.843769 ↗
Pancreatic adenocarcinoma in liver transplant recipients: a case series. First author DOI 10.21037/apc-21-4 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Richard David Schulick · 2 shared papers, 2023–2025 · strength 0.45
- Paper Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioper… DOI 10.3390/cancers18010094 ↗
- Paper Comparison of Invasive Pancreatic Ductal Adenocarcinoma versus Intraductal Papillary Mucinous Neoplasm: A National Canc… DOI 10.3390/cancers15041185 ↗
Georgios K. Glantzounis · 1 shared paper, 2025 · strength 0.27
- Paper Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioper… DOI 10.3390/cancers18010094 ↗
Georgios Charalambos Sotiropoulos · 1 shared paper, 2025 · strength 0.27
- Paper Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioper… DOI 10.3390/cancers18010094 ↗
Charalampos Theocharopoulos · 1 shared paper, 2025 · strength 0.27
- Paper Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioper… DOI 10.3390/cancers18010094 ↗
Argyrios Gyftopoulos · 1 shared paper, 2022 · strength 0.22
- Paper The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer. DOI 10.3389/fonc.2022.843769 ↗
Dimitrios Moris · 1 shared paper, 2022 · strength 0.22
- Paper The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer. DOI 10.3389/fonc.2022.843769 ↗
Andrew S. Barbas · 1 shared paper, 2022 · strength 0.22
- Paper The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer. DOI 10.3389/fonc.2022.843769 ↗
Marco Del Chiaro · 1 shared paper, 2023 · strength 0.18
- Paper Comparison of Invasive Pancreatic Ductal Adenocarcinoma versus Intraductal Papillary Mucinous Neoplasm: A National Canc… DOI 10.3390/cancers15041185 ↗
Muhammad A. Rauf · 1 shared paper, 2021 · strength 0.15
- Paper Pancreatic adenocarcinoma in liver transplant recipients: a case series. DOI 10.21037/apc-21-4 ↗
Lea K. Matsuoka · 1 shared paper, 2021 · strength 0.15
- Paper Pancreatic adenocarcinoma in liver transplant recipients: a case series. DOI 10.21037/apc-21-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.